Candel Therapeutics (CADL) to Join Russell 3000 Index

Go back to Candel Therapeutics (CADL) to Join Russell 3000 Index

Candel Therapeutics to Join Russell 3000® Index

June 11, 2024 8:00 AM UTC

NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as... More